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Abstract
Background: Hundreds of genes with differential DNA methylation of promoters have been identified for various cancers.
However, the reproducibility of differential DNA methylation discoveries for cancer and the relationship between DNA
methylation and aberrant gene expression have not been systematically analysed.
Methodology/Principal Findings: Using array data for seven types of cancers, we first evaluated the effects of experimental
batches on differential DNA methylation detection. Second, we compared the directions of DNA methylation changes
detected from different datasets for the same cancer. Third, we evaluated the concordance between methylation and gene
expression changes. Finally, we compared DNA methylation changes in different cancers. For a given cancer, the directions
of methylation and expression changes detected from different datasets, excluding potential batch effects, were highly
consistent. In different cancers, DNA hypermethylation was highly inversely correlated with the down-regulation of gene
expression, whereas hypomethylation was only weakly correlated with the up-regulation of genes. Finally, we found that
genes commonly hypomethylated in different cancers primarily performed functions associated with chronic inflammation,
such as ‘keratinization’, ‘chemotaxis’ and ‘immune response’.
Conclusions: Batch effects could greatly affect the discovery of DNA methylation biomarkers. For a particular cancer, both
differential DNA methylation and gene expression can be reproducibly detected from different studies with no batch
effects. While DNA hypermethylation is significantly linked to gene down-regulation, hypomethylation is only weakly
correlated with gene up-regulation and is likely to be linked to chronic inflammation.
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Introduction
Methylation arrays have been used to identify hundreds of genes
with differential DNA methylation of their promoters in various
types of cancers [1,2,3,4], hereafter referred to as DM genes,
providing insights into cancer biology and useful biomarkers for
predicting cancer outcomes and drug targets [5]. However,
various biological and technical factors may affect the discovery
of biomarkers for human cancers. In particular, batch effects,
which could be introduced by using samples from different
experimental batches (such as sample preparation at different
times, with different protocols, on different chip lots or different
microarray platforms), may produce systematic non-biological
differences between different groups of samples [6,7,8,9]. Thus, a
challenging task of fundamental importance for biomarker
validation is to evaluate the reproducibility of DM gene discovery
across different studies for a particular cancer [10,11,12]. This
problem has not been fully addressed until now. Once DM genes
are reproducibly identified for a particular cancer, an important
task is to define their roles in cancer development. It is widely
accepted that aberrant promoter methylation is a significant cause
of altered gene expression in cancer [13]. However, several recent
studies have challenged the inverse correlation between methyl-
ation and expression changes [14,15]. Thus, the relationship
between changes in DNA methylation and gene expression in
cancer still needs to be systematically evaluated.
The Cancer Genome Atlas (TCGA) database [16] provides
hundreds of methylation profiles for various cancer types. For a
particular cancer, samples were often collected from different
laboratories and treated in different experimental batches due to
practical complications such as technology limitation. In this
paper, based on methylation profiles for nine types of cancer
collected in the TCGA database [16], we showed that improperly
integrating data from different experimental batches to extract
DM genes could be misleading. After excluding datasets with
potential batch effects, we demonstrated that the change of
methylation states (hypermethylation or hypomethylation) of DM
genes in cancer samples compared with normal samples can be
highly reproducibly detected from different datasets for a given
cancer. A similar trend was observed for the expression changes of
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Expression Omnibus database [17]. Then, based on the
reproducible DM and DE genes for each cancer type, we
determined that the promoter hypermethylation is highly inversely
correlated with the gene down-expression, whereas hypomethyla-
tion is only weakly correlated with the up-expression of genes with
large expression changes. At last, we found that hypomethylated
genes mainly disturb functions directly linked to chronic
inflammation, such ‘chemotaxis’ and ‘immune response’ functions.
Materials and Methods
Data sources
The expression and methylation datasets described in Table 1
and Table 2 were downloaded from the GEO [17] and TCGA
[16] databases, respectively. The raw gene expression profiles were
normalised using the robust multi-array analysis (RMA) algorithm
[18]. We used the level 2 data defined in the TCGA database,
which provides U (unmethylated) and M (methylated) values for
each probe. The Beta values of the probes were calculated by M/
(U+M+100) [19]. The probe IDs were mapped to Gene IDs with
the annotation table for each platform.
Analysis of batch effects
The batch effects could be generated for samples from different
experimental batches or collection centres in the TCGA database
[16]. For the methylation data from TCGA, we computed an F-
statistic to test for the correlation between probes’ methylation
levels (Beta values) and their experimental batches or collection
laboratories. The P values were adjusted by the Bonferroni-
Hochberg procedure with the false discovery rate (FDR),0.05
[20] and significant probes were considered susceptible to batch
effects [9]. To evaluate the effect of experimental batches on DM
gene detection, we also compared DM genes selected from
datasets compromising tumour samples from different batches and
a given group of normal samples from a batch for a particular
cancer type.
Selection of DM genes and DE genes
For each dataset, we selected DM genes with t-test [19] and
used the Benjamini-Hochberg procedure to control the FDR at a
given level [20]. The DM genes with larger means of methylation
levels in the cancer samples than in the normal samples were
defined as hypermethylated genes; otherwise, the DM genes were
defined as hypomethylated genes.
Differentially expressed (DE) genes were selected using the SAM
(significance analysis of microarray) algorithm [21]. Genes with
adjusted P values less than 0.05 were defined as differentially
expressed (DE) genes.
Reproducibility analysis of DM genes and DE genes
Then, we evaluated the reproducibility of DM gene detection
by analysing the overlap of the lists of DM genes selected from two
datasets for each cancer. If k genes are shared by list 1 with length
L1 and list 2 with length L2, then the POG (percentage of
overlapping genes) score from list 1 (or list 2) to list 2 (or list 1) is
POG12=k/L1 (or POG21=k/L2). Next, we evaluated the
consistency of the methylation directions (hypermethylation or
hypomethylation) of the k genes shared by lists 1 and 2 across the
two datasets. The same analysis was performed on the lists of DE
genes selected from two expression datasets for each cancer.
Concordance between DNA methylation and gene
expression changes
If the expression of a hypermethylated (or hypomethylated)
gene was significantly down-regulated (or up-regulated), we
considered the methylation change to be concordant to the
change in gene expression. We defined the concordance rate
between DNA hypermethylation and gene down-regulation as the
percentage of down-regulated genes among the hypermethylated
genes with differential expression. The P value was calculated by
the hypergeometric model [10,11,12]. Similarly, the concordance
rate between DNA hypomethylation and gene up-regulation was
defined as the percentage of up-regulated genes among the
hypomethylated genes with differential expression.
Function enrichment of DM genes
Using Elim software, we detected Gene Ontology (GO) terms
enriched with DM genes [22]. The P values were adjusted by the
Bonferroni-Hochberg procedure with an FDR,0.05 [20].
Results
Batch effects on DM gene detection
We first evaluated the effects of experimental batches on the
methylation level for each probe in the tumour samples of two
batches separately for nine types of cancers collected in the TCGA
database(see Table 1) using the F-statistic with an false discovery
rate (FDR),0.05 [20] (see Methods). As shown in Fig. 1a, about
30% of probes, on average, were significantly susceptible to batch
Table 1. The datasets of nine cancer types for analyzing batch effects.
Cancer type Abbreviation
Number
of batch
Number of
Laboratory
Number of
Tumour samples
Number of
normal samples
Ovarian serous cystadenocarcinoma OV 13 17 520 35
Colon adenocarcinoma COAD 9 5 168 23
Lung adenocarcinoma LUAD 4 11 128 27
Lung squamous cell carcinoma LUSC 5 12 115 31
Stomach adenocarcinoma STAD 3 3 82 61
Kidney renal clear cell carcinoma KIRC 6 10 219 205
Glioblastoma multiforme GBM 9 13 264 5
Breast invasive carcinoma BRCA 3 9 186 2
Rectal adenocarcinoma READ 5 4 70 7
doi:10.1371/journal.pone.0029686.t001
Differential DNA Methylation and Gene Expression
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laboratories and different batches. And about 20% probes were
still significantly susceptible when restricted samples from the same
laboratory but treated in different batches (Fig. 1b). However, only
about 7.7% probes were significantly susceptible when samples
came from the same batches (Fig. 1c). Especially, as shown in
Fig. 1d, the tumour samples from two batches (batch 9 and batch
12) for ovarian serous cystadenocarcinoma could be clustered
together perfectly according to batch by the hierarchical clustering
algorithm using the Euclidean distances of the Beta values between
samples.
The above results indicated that integrating tumour samples
from different batches to detect DM genes might be misleading. In
fact, as a result of the batch effects, the change of methylation
states of DM genes in cancer samples compared with normal
samples could be highly inconsistent when comparing tumour
samples from different batches with the same group of normal
controls (see Fig. 2). For example, when comparing tumour
Table 2. The Methylation and Expression datasets of five cancer types for concordance analysis.
Cancer type Methylation
# Database Expression
# Database
Colon adenocarcinoma C22 TCGA c23 GSE4183
C44 GSE17648 c64 GSE8671
Kidney renal clear cell carcinoma K78 TCGA k20 GSE6344
K100 TCGA k34 GSE15641
Stomach adenocarcinoma S24 TCGA NA
S94 TCGA
Lung adenocarcinoma La8 TCGA la52 GSE7670
La14 TCGA la107 GSE10072
Lung squamous cell carcinoma Ls24 TCGA NA
Ls28 TCGA
Platform Illumina HumanMethylation27 BeadChip Affymetrix Human Genome U133 (GPL96,GPL570)
#Each dataset is denoted by the following nomenclature: initial character of the cancer type followed by the total number of samples of the dataset; NA, not available.
doi:10.1371/journal.pone.0029686.t002
Figure 1. Batch effects on tumour samples for nine cancer types. (a) different batches and different laboratories; (b) the same laboratory but
different batches; (c) the same batch but different laboratories; (d) Hierarchical clustering the tumour samples of ovarian serous cystadenocarcinoma
in batch 9 and batch 12. For a cancer type denoted in the x-axis in graph a, b or c, a box plot in the y-axis represents the percentage of probes
significantly susceptible to different batch conditions. The percentage takes value ranging from 0 (no susceptible probe) to 1 (100% susceptible
probes). Each box stretches from the lower hinge (defined as the 25th percentile) to the upper hinge (the 75th percentile) and the median is shown
as a line across the box.
doi:10.1371/journal.pone.0029686.g001
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cystadenocarcinoma with the same group of normal samples
(batch 27), respectively, the consistency of the change of
methylation states of the common DM genes was only 23.5%.
Therefore, most of the observed differential methylation was
across batches rather than across biological groups, leading to
highly irreproducible results.
Reproducibility of DM gene detection
To avoid potential batch effects and bias which could be
introduced by different ages of the patients, we only analysed the
profiles of five cancer types for each of which pair-matched tumour
and normal samples from the same patients collected by the same
laboratory and measured in the same experimental batch were
available (see Table 2). For each cancer, we used the two largest
batches as independent datasets and detected DM genes with t-test
at FDR,0.05 [20]. Then, we evaluated the consistency of the two
lists of DM genes detected separately from the two datasets (batches)
by calculating the percentage of overlapping genes (POG) between
thetwo listsofDMgenes[10] (see Methods). Foreach cancer, most of
the DM genes on the shorter list were included in the longer list, as
reflected by the POG12 scores shown in Table 3. More than 99% of
the DM genes detected in both datasets were consistent in the
change of methylation states across the two datasets. For example,
3778 and 3966 DM genes were separately identified in the two
datasets (K78 and K100, respectively) for kidney renal clear cell
carcinoma (kidney cancer), with an overlap of 3443 genes.
Strikingly, all of the 3443 genes showed the same change of
methylation states across the two datasets, significantly more than
expected by chance (Bernoulli model P,2.2610
216).
Figure 2. Batch effects on DM genes of six cancer types. For each cancer type denoted in the x-axis, a box plot in the y-axis represents the
consistency score defined as the proportion of DM genes with consistent methylation states among all overlapping DM gene commonly detected in
both of the two groups (see ‘Methods’ section). The consistency score takes value ranging from 0 (no consistent states) to 1 (100% consistent states).
Each box stretches from the lower hinge (defined as the 25th percentile) to the upper hinge (the 75th percentile) and the median is shown as a line
across the box.
doi:10.1371/journal.pone.0029686.g002
Table 3. Consistency of DM genes across different datasets for each cancer.
Dataset
# DM-S
* DM-L
** Overlap POG12
$ POG21
$$ Consistency
¥
C22–C44 2601 4001 2421 93.1% 60.1% 99.9%
K78–K100 3778 3966 3443 91.1% 86.8% 100%
La8–La14 752 1698 488 64.9% 28.7% 99.6%
S24–S94 2274 4867 2210 97.2% 45.4% 100%
Ls24–Ls28 2682 2909 2152 80.2% 74.0% 100%
#Each dataset was denoted by the following nomenclature: initial character of the cancer type followed by the total number of samples of the dataset.
*DM-S denotes DM genes from the shorter list;
**DM-L denotes DM genes from the longer list.
$POG12 denotes the score from the shorter list to the longer list;
$$POG21 denotes the score from the longer list to the shorter list.
¥Consistency denotes the percentage of overlapping genes which showed the same methylation directions across the two datasets.
doi:10.1371/journal.pone.0029686.t003
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determined to be significant in another dataset for each cancer, as
reflected by the POG21 scores shown in Table 3. However, our
analysis showed that most of the DM genes that were solely
detected in one dataset also showed the same change of
methylation states in another dataset for the same cancer,
revealing that the effective biological signals of these DM genes
also existed in the other dataset. For example, for kidney cancer,
514 (98.2%) of the 523 genes detected to be significant solely in the
larger dataset (K100) showed the same change of methylation
states in the smaller dataset (K78), which was highly unlikely to
happen by chance (Bernoulli P,2.2610
216). Thus, the relatively
low POG21 scores might reflect a reduced statistical power for
detecting DM genes in the smaller dataset, coupled with a
stringent FDR control [10,23].
We also analysed an independent dataset for colon cancer
available from the GEO database [17]. With FDR,0.05, 2601
and 4001 DM genes were identified in the C22 dataset (from
TCGA) and the C44 dataset (from GEO), respectively. These two
lists of DM genes shared 2421 genes, among which 2419 (99.9%)
showed the same change of methylation states across the two
datasets (Bernoulli model P,2.2610
216). Among the other 1582
genes that were significant in the larger C44 dataset but not in the
smaller C22 dataset, 1502 (94.9%) showed the same change of
methylation states in the smaller dataset, significantly more than
expected by chance (Bernoulli model P,2.2610
216). The high
consistency of the change of methylation states for the DM genes
across different datasets for the same cancer indicated that DM
genes in cancer could be reproducibly detected in high-throughput
methylation data.
Reproducibility of DE gene detection
The TCGA data are also problematic for expression data
because only one normal sample were measured in expression for
each cancer, which makes the comparison between tumour and
normal samples unreliable. Therefore, we selected expression data
of matched cancer type from GEO database [17]. For nine
cancers analysed above, we were able to find two gene expression
datasets for three cancers (see Table 2). For each of these three
cancers, using SAM [21] with FDR,0.01, we selected two lists of
differentially expressed (DE) genes from the two datasets and
found that most of the DE genes in the shorter list were included in
the longer list, as reflected by the POG12 scores shown in Table 4.
In addition, over 94.5% of the DE genes detected in both of the
datasets for each cancer were consistent in the regulation direction
(up or down) across the two datasets, which was highly unlikely to
happen by chance (Table 4, Bernoulli model P,2.2610
216). In
addition, most of the DE genes solely detected in one dataset
showed the same regulation directions in another dataset for the
same cancer, revealing that the effective biological signals of these
DE genes existed in the later dataset. For example, for colon
cancer, 6056 (94.5%) of the 6420 genes detected to be significant
solely in the larger dataset (c64) showed the same regulation
direction in the smaller dataset (c23), which is highly unlikely to
happen by chance (Bernoulli model P,2.2610
216).
The above analyses were based on data normalised by the RMA
algorithm, which assumes that the majority of genes are not
differentially expressed in a disease [24]. We performed the same
analyses using the least-variant set (LVS) algorithm [25], which
relies less on this assumption, and the results were similar.
Concordance between differential methylation and
differential expression
The above results indicated that the methylation and expression
changes could be reproducibly detected across different datasets
for a particular cancer. Notably, although the expression
microarray data from different sources, rather than the TCGA
data itself, the highly consistency of expression change across two
datasets from the same cancer indicated the gene regulation
directions were reproducible and reliable for the specific type of
cancer. Therefore, based on the reproducible DM and DE genes
of the same cancer type, we examined the influence of gene
promoter methylation on gene expression. Briefly, if a hyper-
methylated (or hypomethylated) gene found by methylation data
was significantly down-regulated (or up-regulated) in the expres-
sion data, we considered that its DNA methylation was concordant
to its expression change. The concordance rate was measured by
the percentage of hypermethylated (or hypomethylated) genes
concordant to gene down-regulation (or up-regulation).
We evaluated the concordance between differential methylation
and expression at two levels. First, we evaluated the concordance
between differential methylation and differential expression of
genes. As shown in Table 5, 91.6%, 86.6% and 88.2% of the
hypermethylated genes were down-regulated in colon, kidney and
lung cancers, respectively, indicating that hypermethylation is
significantly correlated with down-regulation of genes (hypergeo-
metric test P,1.0610
25 for all three cancers). For example, in
colon cancer, 98 of the 107 hypermethylated genes were down-
regulated in cancer samples compared with normal controls
(hypergeometric test P=7.8610
29). Then, we focused on the
concordance between methylation with great methylation level
change and expression with great fold change (FC) between
tumour and normal samples. When we focused on DM genes with
at least 0.15 Db (difference of the mean methylation levels between
tumour and normal samples), the concordance rates increased to
96.1%, 96.2% and 91.3% for colon, kidney and lung cancers,
respectively. Similarly, when we focused on reproducible DE genes
with at least a 2-fold change (FC), the concordance rates for the
three cancers were all above 90%. However, the relationship
between the hypomethylation of genes and the up-regulation of
gene expression is rather elusive. The concordance rates were
50.3%, 39.4% and 62.5% for colon, kidney and lung cancers,
Table 4. Consistency of DE genes across different datasets for each cancer.
Dataset
# DE-S
* DE-L
** Overlap POG12
$ POG21
$$ Consistency
c23–c64 2733 9098 2678 97.9% 29.7% 100%
k20–k34 4309 6045 2856 66.3% 47.2% 94.5%
la52–la107 3691 5920 3260 88.3% 55.1% 100%
*DE-S denotes DE genes from the shorter list;
**DE-L denotes DE genes from the longer list.
doi:10.1371/journal.pone.0029686.t004
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significant inverse correlation with gene up-regulation (hypergeo-
metric test P=4.2610
26). When we focused on DM genes with at
least 0.15 or 0.3 Db, the hypomethylation was significantly
correlated with the up-regulation of gene expression only in lung
cancer. When we examined the DE genes with at least a 2-fold
change, the concordance rates increased to 58.5% and 61.7% for
colon and kidney cancers, respectively, and became significant
(hypergeometric test P=2.7610
27 and 5.4610
24, respectively).
Notably, the concordance rates were approximately 60% even
after the FC cut-off for the three cancers. These results suggest that
hypomethylation may partially affect up-regulation of gene
expression with large fold changes.
Functions of hypermethylated genes and
hypomethylated genes
Using Elim software with FDR,0.05 [22], we detected GO
terms significantly enriched with hypermethylated genes repro-
ducibly identified in the two datasets for each cancer. For colon
cancer, we found 58 significant terms, which were associated with
basic biological processes such as transcription, cell adhesion and
signalling (Supplementary Table S1 for detailed terms). For kidney
cancer, we found 14 significant terms, among which 11 were
included in the significant terms for colon cancer, suggesting that
hypermethylated genes in these two cancers tend to be involved in
similar functions. However, no significant GO term was found for
lung cancer with FDR,0.05. By comparing the top 10 terms with
the smallest P values for the three cancers, we found that 4 terms
were shared by colon and kidney cancers, and neither cancer
shared a term with lung cancer. These results indicated that the
hypermethylation pattern of lung cancer may be different from
those of colon and kidney cancers.
With FDR,0.05, we found 14, 29 and 2 GO terms enriched
with hypomethylated genes for colon, kidney and lung cancers,
respectively (Supplemental Table S2). Most of these significant
terms were related to immune response. A comparison of the lists
of the top 10 terms with the smallest P values for the three cancers
showed that they shared three terms: ‘keratinization’, ‘defense
response to bacterium’, and ‘cellular defense response’. We
additionally tested the function of hypomethylated genes from
Lung squamous cell carcinoma and Stomach adenocarcinoma
data. These genes were also enriched in ‘keratinization’ and
‘defense response to bacterium’ (Supplemental Table S3).
Specifically, in‘keratinization’, we found that 12 KAP genes
encoding keratin associated proteins (Table 6) were hypomethy-
lated in all five types of cancers. Notably, these 12 KAP genes were
also included in the 16 KAP genes found to show pronounced
differential hypomethylation in bladder cancer [26]. These
evidences together suggest that KAP genes could be used as
biomarkers for multiple cancers. Finally, a comparison of two of
the three cancers revealed that the DM genes detected solely in a
particular cancer were more likely to be hypermethylated than the
DM genes detected in two cancers (chi-squared test P,0.001 for
the comparison of the proportions of hypermethylated genes). For
example, 635 (43.5%) of the 1411 DM genes detected in colon
cancer but not in lung cancer were hypermethylated, while only 42
(16.5%) of the 254 DM genes detected in both cancers were
hypermethylated. On the other hand, 168 of the 189 DM genes
shared by the three cancers were hypomethylated and enriched in
‘keratinization’, ‘chemotaxis’, and ‘immune response’ functions
(see Discussion).
Discussion
The detection of aberrant DNA methylation in cancer can yield
important biomarkers for predicting cancer outcomes and drug
targets. However, pitfalls in experiment designs and faulty data
analyses, such as improperly integrating batches of TCGA data,
may produce unreliable biomarkers [9]. Notably, most studies
using the TCGA data, including many published in high-profile
journals [16,27,28,29], did not considered the potential batch
effects, which would be likely to produce misleading results
associated with the batches rather than the biological outcomes.
For example, Houtan et al. [27] integrated glioblastoma tumour
samples from several batches and identified a distinct subset of
samples displaying concerted hypermethylation, which might have
been correlated with their experimental batches similarly to the
data shown in the clustering map in Fig. 1d. Therefore, we
suggested that the conclusions based on integrated samples should
be re-evaluated by considering potential batch effects. Our results
strongly suggest that, an experiment should be designed to avoid
the batch effect by equally distributing possible experimental
Table 5. Concordance between differential methylation and differential expression.
Cancer types Hypermethylation Hypomethylation
Gene
1 number Concordance rate P value Gene
1number Concordance rate P value
Colon 107 91.6% 7.7*10
29 157 50.3% 0.99
Kidney 254 86.6% 1.5*10
212 302 39.4% 0.397
Lung 34 88.2% 1.5*10
26 88 62.5% 4.2*10
26
1Gene number denotes the number of hypermethylated (or hypomethylated) genes which were determined to be differentially expressed in the expression data.
doi:10.1371/journal.pone.0029686.t005
Table 6. Keratin associated protein genes hypomethylated in
five cancers.
GeneID Gene Name GeneID Gene Name
337880 keratin associated
protein 11-1
337972 keratin associated
protein 19-5
140258 keratin associated
protein 13-1
337976 keratin associated
protein 20-2
337960 keratin associated
protein 13-3
337977 keratin associated
protein 21-1
284827 keratin associated
protein 13-4
337978 keratin associated
protein 21-2
254950 keratin associated
protein 15-1
337979 keratin associated
protein 22-1
337882 keratin associated
protein 19-1
337879 keratin associated
protein 8-1
doi:10.1371/journal.pone.0029686.t006
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for each group [9].
Our results showed that DM genes detected from different
datasets for the same cancer, excluding batch effects, were
consistent in methylation across the datasets, similar to the
observation that DE genes detected from various microarray
studies show a consistent up or down expression pattern
[10,30,31]. Thus, the signals of the methylation states of DM
genes in cancer can be reliably detected in methylation arrays.
Notably, 36 of the 47 hypermethylation genes of colon cancer
documented in the Methycancer database [32] were found to be
DM genes in our colon cancer data, among which 34 were also
hypermethylated (Supplementary Table S4). The reproducible
methylation biomarkers in different cohorts of patients could
provide valuable information for finding prognostic biomarkers
and drug targets for cancers.
On the other hand, we found that, for a particular cancer, many
DM genes detected in one dataset may not be significant in
another dataset due to the insufficient power of detecting DM
genes in small samples coupled with stringent FDR control
[10,30,33]. The reduction of power could lead to the selection of
the most significant genes as biomarkers for a cancer to be highly
unstable across different studies [34]. To evaluate the reproduc-
ibility of the most significant DM genes discovered from different
studies for a particular cancer, we could take into account the
functional relationship rather than simply counting the overlaps
[11,35].
For the function of DM genes, our results showed hypermethy-
lation of gene promoters was significantly linked to the down-
regulation of gene expression in cancer and affects basic biological
processes, such as signalling and cell growth, similar to what has
been observed for human ageing [36]. By contrast, hypomethyla-
tion was only weakly correlated with gene up-regulation,
indicating that other factors such as gene body hypermethylation
[37] and copy amplification [38] may contribute more to the up-
regulation of gene expression. We found that hypomethylated
genes for different cancers were similar in functions directly linked
to chronic inflammation, such as ‘chemotaxis’ and ‘immune
response’. Chemokines play important roles in regulating
inflammation progress [39], and immune deficiency can result in
chronic inflammation [39]. This chronic inflammation may
induce global hypomethylation, which may cause chromosome
instability and increase mutations of the genome and then increase
the risk of cancer [40].
Additionally, our results showed that DM genes detected in a
specific type of cancer were more likely to be hypermethylated
than DM genes detected in multiple cancers. However, defining
cancer type-specific biomarkers is difficult because different studies
for a particular cancer frequently discover different DM genes.
Using the tissue-specific genes collected by Xiong et al. [41], we
found that genes preferentially expressed in a specific tissue were
enriched with genes differentially methylated in the corresponding
cancer type (hypergeometric test P,0.001 for all three cancers),
but these DM genes did not show any preference toward
hypermethylation or hypomethylation. Considering that the
accuracy of ‘‘tissue-specific’’ genes strongly depends on the
expression level of the respective transcript [42], it might be more
reliable to define ‘‘tissue-specific’’ genes by their methylation
patterns [43]. In future work, we plan to study cancer type-specific
DM genes by taking into account the opposite methylation
directions of DM genes detected for different cancer types.
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